Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions.

about

Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions.

Item

http://www.wikidata.org/entity/Q47195199

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Usefulness of simultaneous and ...... and nonrestricted conditions.

@en

Usefulness of simultaneous and ...... and nonrestricted conditions.

@nl

type

Item

label

Usefulness of simultaneous and ...... and nonrestricted conditions.

@en

Usefulness of simultaneous and ...... and nonrestricted conditions.

@nl

prefLabel

Usefulness of simultaneous and ...... and nonrestricted conditions.

@en

Usefulness of simultaneous and ...... and nonrestricted conditions.

@nl

P1476

Usefulness of simultaneous and ...... and nonrestricted conditions.

@en

P2093

Katsuyoshi Chiba

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Mori

http://www.w3.org/2001/XMLSchema#string

Tomomichi Ishizaka

http://www.w3.org/2001/XMLSchema#string

Yu Yoshimatsu

http://www.w3.org/2001/XMLSchema#string

P2860

Outpatient gatifloxacin therapy and dysglycemia in older adults

In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone

Hypoglycemia in diabetes.

Gatifloxacin produces both hypoglycemia and hyperglycemia: a retrospective study.

Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats.

Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring.

Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.

Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

Impact of glucose concentration on cardiac ventricular repolarization under I Kr/I Ks blocking agents.

P304

281-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1538/EXPANIM.17-0136

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29311442

http://www.w3.org/2001/XMLSchema#string

P921

electrocardiography

glucose monitoring

P932

5955759

http://www.w3.org/2001/XMLSchema#string